A new report from the Alzheimer’s Association highlights the potential benefits of using newer, more accurate diagnostic testing methods to detect and treat Alzheimer’s disease. The tests, which are not yet approved for everyday use, have shown significant improvement in accuracy rates up to 91% in research studies.
Currently, doctors rely on expensive and invasive procedures such as PET scans or spinal taps to diagnose the disease. However, these tests can be costly and difficult to access. In contrast, blood tests could provide a simpler and more accessible way to identify early signs of Alzheimer’s.
The report also emphasizes the importance of early diagnosis in accessing effective treatments that can slow the progression of the disease. Two new drugs, Leqembi and Kisunla, have been approved by the FDA in the past two years, which can help preserve memory and thinking skills longer.
However, these new treatments come with challenges, including high costs, frequent monitoring requirements, and risks associated with side effects. The report notes that more than 140 different treatments are currently under development to target various symptoms and stages of Alzheimer’s.
The Alzheimer’s Association also highlights the importance of addressing modifiable risk factors, such as diet, exercise, and blood pressure, which can have a significant impact on reducing the risk of developing Alzheimer’s disease. Nearly half of all dementias could be preventable by taking better care of these modifiable risks earlier in life.
The report announces the launch of ALZ-NET, a nationwide tracking system that follows patients in real-time to collect data on the long-term safety and effectiveness of new medications. This initiative aims to improve care for Alzheimer’s and other dementia patients by providing faster diagnosis and access to treatment.
Source: https://abcnews.go.com/Health/alzheimers-society-calls-doctors-newer-early-diagnostic-testing/story?id=121163860